Ravulizumab as an alternative for gemcitabine related trombotic microangiopathy: A case report.

Thrombotic microangiopathy (TMA) is characterized by endotelial damage, microangiopathic hemolytic anemia, thrombocytopenia and organ damage, particularly renal. In Oncology, TMA can be secondary to the cancer itself or related to oncological treatme…

Preview only. Read the full abstract at the source